146 related articles for article (PubMed ID: 26199249)
1. [Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
Morimoto T; Yata Y; Yonenaga Y; Hanaki K; Mise M; Higaside S; Kanda Y; Noda H
Gan To Kagaku Ryoho; 2015 Jun; 42(6):743-5. PubMed ID: 26199249
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
3. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
[TBL] [Abstract][Full Text] [Related]
4. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
[TBL] [Abstract][Full Text] [Related]
6. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
8. [Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].
Maruo H; Suzuki K; Ishikawa S; Murakami T; Higashi Y; Shoji T; Yamazaki M; Taniguchi M; Nishiyama R
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2583-6. PubMed ID: 25596052
[TBL] [Abstract][Full Text] [Related]
9. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
[TBL] [Abstract][Full Text] [Related]
10. Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.
Liu H; Wang Y; Li G; Song W; Wang R
J Cancer Res Ther; 2015; 11(2):331-5. PubMed ID: 26148595
[TBL] [Abstract][Full Text] [Related]
11. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of S-1 in colorectal cancer.
Miyamoto Y; Sakamoto Y; Yoshida N; Baba H
Expert Opin Pharmacother; 2014 Aug; 15(12):1761-70. PubMed ID: 25032886
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).
Yoshida M; Muro K; Tsuji A; Hamamoto Y; Yoshino T; Yoshida K; Shirao K; Miyata Y; Takahari D; Takahashi T; Ohtsu A
Eur J Cancer; 2015 May; 51(8):935-41. PubMed ID: 25837882
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).
Mukai T; Uehara K; Goto H; Hiramatsu K; Kobayashi S; Sakamoto E; Maeda A; Takeuchi E; Okada Y; Ebata T; Nagino M;
Jpn J Clin Oncol; 2017 Jul; 47(7):597-603. PubMed ID: 28398493
[TBL] [Abstract][Full Text] [Related]
15. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
16. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
[TBL] [Abstract][Full Text] [Related]
17. Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):4029-32. PubMed ID: 24023346
[TBL] [Abstract][Full Text] [Related]
18. [A case of disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation caused by advanced colon cancer successfully treated with SOX/bevacizumab].
Suzuki H; Matsuoka N; Ushimaru Y; Kakimoto Y; Toyoda A; Endo Y; Murakami O; Kato Y; Inoue M; Kimura T; Matsuda Y; Sasakabe H
Gan To Kagaku Ryoho; 2014 Aug; 41(8):1013-6. PubMed ID: 25132036
[TBL] [Abstract][Full Text] [Related]
19. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
Hong J; Han SW; Ham HS; Kim TY; Choi IS; Kim BS; Oh DY; Im SA; Kang GH; Bang YJ; Kim TY
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1323-31. PubMed ID: 20734048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
